HIGH SCHOOL EDITION
Journal of Student Research
Volume 12 Issue 3 (2023)

Intersections of Artificial Intelligence, Brain Imaging Tools and Diagnostics for Neurodegenerative Diseases

Anish Jayaraj
Evergreen Valley High School

ABSTRACT

This paper explores the fascinating topics of artificial intelligence (AI), brain imaging tools, and diagnostics for neurodegenerative diseases. By examining the advancements in AI algorithms and their integration with cutting-edge brain imaging technologies, this publication displays the potential of these approaches to revolutionize the diagnoses and understanding of neurodegenerative disorders. Through an analysis of recent studies, this paper highlights the significant progress made by utilizing AI-powered tools, enhancing the accuracy, efficiency, and early detection of conditions such as Alzheimer's, Parkinson's, and Huntington's diseases. Ultimately, this research underscores the transformative role that AI and brain imaging can play in the field of neurodegenerative disease diagnostics, paving the way for improved patient care and better outcomes.

In addition to exploring the current state of AI and brain imaging tools in neurodegenerative disease diagnostics, my paper also dives into the potential future applications and challenges in this rapidly evolving field. It discusses the ethics of AI-driven diagnostic methods, emphasizing the importance of ensuring patient privacy, informed consent, and equitable access to these technologies.

Introduction

As neuroscientists utilize the advancements in technological tools and assessment scans and diagnostic imaging to identify brain functionalities and impairments associated with neurodegenerative diseases, findings are helping researchers better understand the onset of Parkinson's disease and Huntington's disease. With the introduction of Artificial Intelligence that has been used now to analyze biomarkers that can predict early detection of neurodegenerative diseases, alongside novel brain imaging tools that are being used to diagnose patients, it is clear that the combination of these technological tools and scans helps researchers better establish preventable cures, solutions and treatment plans that can be tailored to patients diagnosed with certain impairments on their brain. This paper will cover both their ethical contradictions and research limitations, findings surrounding interdisciplinary research, alongside general frameworks that have been established already by neuroscientists and researchers. Furthermore, the publication reiterates the need for continued research and collaboration between scientists and technology experts to optimize the performance and reliability of AI for neurodegenerative disease diagnosis.

AI and its Applications in Neuroscience

As demand for research expands, artificial intelligence has recently emerged as an revolutionary approach to many fields, including cognitive science and neuroscience. It has opened up new ideas for understanding the complexities of the human mind and has revolutionized the way researchers approach interventions in these disciplines. AI has had profound contact within the fields of cognitive science and neuroscience, highlighting the advancements and interventions that have been made possible by this technology. (Murphy, 2019) Cognitive science and neuroscience seek to unravel the mysteries of the human brain and cognition. With the introduction of AI, researchers have gained access to powerful tools and techniques that can enhance their understanding and accelerate progress in these areas.

Machine learning algorithms, in particular, have proven to be immensely valuable in understanding complex brain processes and patterns of human cognition.

Early Detection and Diagnosis with AI – Analyzing Biomarkers for Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's and Parkinson's, pose significant challenges to healthcare systems worldwide. Detecting these diseases at an early stage is crucial for effective intervention and treatment. In recent years, AI has definitely emerged as a powerful tool in analyzing biomarkers to enable early detection and diagnosis of neurodegenerative diseases. This article dives into the fascinating subtopic of AI and biomarker analysis, highlighting its potential to revolutionize early intervention strategies of diseases. Biomarkers are measurable indicators that reflect physiological and pathological processes occurring in the body. In the case of neurodegenerative diseases, specific biomarkers can serve as early warning signs, allowing for timely intervention. This analysis of biomarkers is complex and requires the processing of large datasets, making it an ideal application for AI (Cancian, 2021). Machine identification algorithms can learn from vast amounts of data, identifying patterns and correlations that may not be immediately apparent to human researchers. By training AI models on extensive biomarker datasets, scientists can develop powerful tools for early detection and diagnosis.

Applications and Discussion of AI's Usage For Diagnosing Parkinson's Disease

Parkinson's disease is a neurological disease that progresses at a rapid speed, whereby doctors and physicians have struggled to identify the optimal forms of treatment such as loss of motor control and speech. Thus, novel forms of data-driven AI technology have been integrated to diagnose Parkinson's disease for researching moving forward. Specifically, machine learning has been adapted to predict the behaviors associated with Parkinson's disease across a myriad of databases. Research was enacted, where ill and healthy patients were all reviewed through a boosting committee machine. (Bind et. al., 2015) When Artificial Intelligence was incorporated into the filtering techniques, 75.4% of 195 samples successfully tested positive for Parkinson's Disease. This research was then complemented by another group of researchers (Sachdev et. al., 2014) who proved that the machine learning-oriented approach had a precision of 92.31%, where the machine learning diagnostic performance has been gradually improving with the development of optimal technologies.

In another research, a new model on a dataset consisting of 7,671 individuals analyzed the AI model and its efficacy in detecting Parkison's Disease at an earlier point. Through applying an AI model that utilizes an attention layer in a touchless manner in a noninvasive assessment form, AI was proven to be a useful tool for risk assessment before clinical diagnosis (Yang et. al., 2022)

Applications for Alzheimer's Disease

As a decline in speech and language are evident markers of Alzheimer's disease, research has been established to underline the use and applications of AI to predict the cognitive decline of patients diagnosed with Alzheimer's disease. Recent introduction of AI algorithms were utilized to display how AI algorithms can better optimize and analyze data in medical imaging, and also provide predictive modeling and monitoring of cognitive function, memory, attention and other executive functions. When a research study was conducted on analyzing 97 relevant studies that classified Alzheimer's disease, aging and other neurodegenerative diseases, it was uncovered

that the optimal performance was achieved through applying the deep learning-based convolution neural network algorithms, that presented a 89% accuracy and efficacy, as compared to a 76% efficacy utilizing logistic regression. (Frizzell et. al., 2012)

In the establishment of the Alzheimer's Disease Neuroimaging Initiative (ADNI) database in 2004, three trials were led on validating biomarkers and various trials within Alzheimer's Disease. When findings were released, it was deciphered that AI has its applications in the fields of neuroimaging, genetics and creating a multimodal approach that can integrate large amounts of clinical and neuropsychological information in varying models. (Spinola, 2022)

Neuroimaging – Analysis of Brain Imaging Technology for Neurodegenerative Diseases

With the advancements in unparalleled technology, diagnosis and monitoring of neurodegenerative diseases has transformed into a paradigm shift — today, biomarkers are included in diagnostic procedures as well as in clinical trials. Today, both MRI and PET scans are utilized to diagnose patients with neurodegenerative disorders, as neuroimaging biomarkers utilized in MRI and PET scans help provide and establish a framework of the patients' brain.

While MRI imaging is notably known for being non-invasive and cost-effective, PET scans on the other hand can help provide more precision in identifying specific issues within the brain. (Chollet, 2012) MRI scans can pinpoint areas of the cortical and subcortical gray matter in the brain, while PET scans on the other hand assess the neuronal function and specific neural targets like the amyloid proteins. (Chollet, 2012)

However, some researchers argue that the combination of utilizing both PET and MRI scans can help foster greater precision, as the combination of both scans would help provide clinical advantages in showcasing biomarkers and integrated imaging that can improve diagnosis through structural and functional information. (Drzezga, 2014) When PET scans were combined with MRI scans for Parkinson's disease, researchers uncovered different clinical interventions from those of dementia. (Barthel, 2015)

Variations of Brain Imaging Technology and Their Efficacy

As more findings continue to be established, researchers are delving into the form of retinal imaging technology that can provide an even more intricate precision of detecting patients at their earlier stages of neurodegenerative diseases. With more technologies being released such as the optical coherence tomography, which has been aided to identify courses of retinal diseases, researchers have been analyzing retina — the sole component of the central nervous system (CNS) that is accessible for high-resolution imaging. By utilizing the retina, neuroscientists have been identifying the sporadic late onset of Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and other neurodegenerative diseases. (Kashani et al., 2021)

However, researchers claim that it is impractical to utilize retinal imaging as the sole diagnostic criteria to analyze for patterns beneath neurodegenerative processes. Specifically, in vivo retinal findings with neurodegenerative diseases can help provide pathological insights; on the other hand, in vivo retinal imaging is considered to be a low-cost form of assessment that can provide and identify appropriate biomarkers.

Neurodegenerative Diseases of the Brain: Analysis of Interdisciplinary Explanations

In a multitude of literature and research publications, researchers have tested for the disease progression of neurodegenerative diseases in varying clinical trials and research settings. Specifically, for instance, analyzing forms of dementia depend on interdisciplinary scopes, by reviewing the foundations of molecular pathology that seems to be evident in the early onset and course of diseases. Additionally, other interdisciplinary research has combined the approaches involving physics, mathematics and machine learning to establish physics-based models that can analyze biofluid and digital biomarkers that point to the onset of neurodegenerative diseases and neuropsychological functions that point to these illnesses. (Davenport, 2023)

Another example has showcased the interdisciplinary combination between neuroscience and microbiology, whereupon utilizing ultra-high field MRI with high exposure to sensitivity, reduced levels of GABA neurotransmitters were evident, thus highlighting their usage in showing research findings to neuroscientists.

Ethical Discussions and Considerations for Integrating Machine Learning, AI and Neuroimaging for Cognitive Diseases

The integration of machine learning, artificial intelligence (AI), and neuroimaging in the field of cognitive diseases raises many important ethical questions and considerations. As these advanced technologies offer promising opportunities for early diagnoses, personalized treatment, and improved patient care, it is crucial to address concerns towards privacy, security, and consent. Additionally, the potential bias in these methods and the impact on vulnerable populations must be kept in mind (Koshimaya, 2021). Transparency in decision-making processes and the responsible use of these technologies should be emphasized to ensure equitable access and prevent unintended consequences. Ethical discussions and guidelines play a substantial role in demonstrating the ethical complexities of integrating machine learning with AI, and neuroimaging into the realm of cognitive diseases, ensuring that advancements in these fields align with the best interests and values of patients and society as a whole (Karimian, 2022).

Conclusion

This publication has explored the fascinating and quickly developing fields of artificial intelligence, brain imaging techniques, and neurodegenerative disease diagnostics. It is clear from a review of recent research and technological developments that AI has the power to fundamentally alter the early detection and diagnosis of these conditions. Brain imaging techniques and AI algorithms combined can give clinicians invaluable insights into the structural and functional changes in the brain, allowing for quicker and more accurate diagnoses.While the mystery surrounding neurodegenerative diseases seemed to be obscured, recent researchers' findings are paving the direction for researchers to look into how AI can be used as a powerful tool and biomarker analysis, how AI can be adapted to better analyze the onset of Parkinson's disease and Alzheimer's disease, alongside how novel forms of brain imaging technology are being used in clinical trials today to identify the rapid onset of these diseases in a non-invasive and cost-efficient manner. While there are still ethical contradictory perspectives behind the importance of retaining privacy, security, patient care and onset, as technology continues to improve, it can be predicted that societal emphasis on cognitive models, brain imaging tools and neuroimaging can help shape the future of patients that have higher susceptibility to brain impairments and extraneous influences from external circumstances. As researchers in the neuroscience industry continue to collaborate with researchers across discipline like those in microbiology and physics, more assessment tools, imaging tools and findings can help enhance diagnosis, treatment, as well as applications for other ethnic groups or age groups that can be delved into, in the future, to diversify the findings discussed in this publication. Finally, we can move closer to better understanding, early intervention, and improved patient quality of life thanks to the convergence of artificial intelligence, brain imaging tools, and diagnostics.

References

Davenport, Franca, et al. "Neurodegenerative Disease of the Brain: A Survey of Interdisciplinary Approaches." *Journal of The Royal Society Interface*, vol. 20, no. 198, 2023, https://doi.org/10.1098/rsif.2022.0406.

Dixit, Shriniket, et al. "A Comprehensive Review on AI-Enabled Models for Parkinson's Disease Diagnosis." *Electronics*, vol. 12, no. 4, 2023, p. 783, https://doi.org/10.3390/electronics12040783.

Drzezga, Alexander, et al. "Potential Clinical Applications of PET/MR Imaging in Neurodegenerative Diseases." *Journal of Nuclear Medicine*, vol. 55, no. Supplement 2, 2014, https://doi.org/10.2967/jnumed.113.129254.

Emre Kazim 1, et al. "A High-Level Overview of AI Ethics." *Patterns*, 10 Sept. 2021, www.sciencedirect.com/science/article/pii/S2666389921001574.

Ghaffari Laleh, Narmin, et al. "Facts and Hopes on the Use of Artificial Intelligence for Predictive Immunotherapy Biomarkers in Cancer." *Clinical Cancer Research*, vol. 29, no. 2, 2022, pp. 316–323, https://doi.org/10.1158/1078-0432.ccr-22-0390.

Shuo Chen a, et al. "Recent Progress and Perspectives on SB2SE3-Based Photocathodes for Solar Hydrogen Production via Photoelectrochemical Water Splitting." *Journal of Energy Chemistry*, 9 Sept. 2021, www.sciencedirect.com/science/article/abs/pii/S2095495621004940.

Silva-Spínola, Anuschka, et al. "The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence." *MDPI*, 29 Jan. 2022, www.mdpi.com/2227-9059/10/2/315.

Ter Haar Romeny, Bart M. "Introduction to Artificial Intelligence in Medicine." *Artificial Intelligence in Medicine*, 2022, pp. 75–97, https://doi.org/10.1007/978-3-030-64573-1_27.

Tory O. Frizzell a b, et al. "Artificial Intelligence in Brain MRI Analysis of Alzheimer's Disease over the Past 12 Years: A Systematic Review." *Ageing Research Reviews*, 28 Mar. 2022, www.sciencedirect.com/science/article/abs/pii/S1568163722000563.